A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Key facts
- Where
- Abington, Atlanta, Auburn, Austin, Cincinnati, Denver, Dublin, El Paso, Henderson, Huntersville, Miami, North Charleston, Orlando, Santa Ana, Sterling Heights, Willow Grove, and Winter Park, United StatesSee the 19 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07096674, who can take part
Where in United States
- Abington, PennsylvaniaAbington, United StatesContact: Orexin Centessa Program LeadTaking people
- Atlanta, GeorgiaAtlanta, United StatesContact: Orexin Centessa Program LeadTaking people
- Stockbridge, GAAtlanta, United StatesContact: Orexin Centessa Program LeadTaking people
- Auburn, AlabamaAuburn, United StatesContact: Orexin Centessa Program LeadTaking people
- Austin, TexasAustin, United StatesContact: Orexin Centessa Program LeadTaking people
- Cincinnati, OhioCincinnati, United StatesContact: Orexin Centessa Program LeadTaking people
- Denver, North CarolinaDenver, United StatesContact: Orexin Centessa Program LeadTaking people
- DublinDublin, United StatesContact: Orexin Centessa Program LeadTaking people
- El Paso, TexasEl Paso, United StatesContact: Orexin Centessa Program LeadTaking people
- Hendersen, NavadaHenderson, United StatesContact: Orexin Centessa Program LeadTaking people
- Henderson, NevadaHenderson, United StatesContact: Orexin Centessa Program LeadTaking people
- Huntersville, North CarolinaHuntersville, United StatesContact: Orexin Centessa Program LeadTaking people
- Miami, FloridaMiami, United StatesContact: Orexin Centessa Program LeadTaking people
- North Charleston, South CarolinaNorth Charleston, United StatesContact: Orexin Centessa Program LeadTaking people
- Orlando, FloridaOrlando, United StatesContact: Orexin Centessa Program LeadTaking people
- Santa Ana, CaliforniaSanta Ana, United StatesContact: Orexin Centessa Program LeadTaking people
- Sterling Heights, MichiganSterling Heights, United StatesContact: Orexin Centessa Program LeadTaking people
- Willow Grove, PennsylvaniaWillow Grove, United StatesContact: Orexin Centessa Program LeadTaking people
- Winter Park, FLWinter Park, United StatesContact: Orexin Centessa Program LeadTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centessa Pharmaceuticals (UK) Limited
- Trial code
- NCT07096674EU 2025-522987-34-00
- Record updated
- 16 April 2026
- Original description
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).Read full original descriptionShow less
A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Inclusion: Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1); Is willing and able to adhere to additional protocol requirements.
Exclusion: Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia; Development of any new disease/disorder that in the opinion of the investigator would make the participant unable to continue the study.